|Articles|July 9, 2019
Tufts: Growth in Rare Disease R&D Challenging Development Strategy and Execution
Advertisement
According to a recently completed analysis from the Tufts Center for the Study of Drug Development, drug development for rare diseases presents scientific and operational challenges that will accelerate the adoption of new development strategies and operating models.
For more on their findings, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
2
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
3
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5